Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Up 6.32%
As of Friday, October 16, Clinuvel Pharmaceuticals Limited’s CUVL share price has surged by 6.32%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Stock Evaluator: Clinuvel Pharmaceuticals Limited (CUVL)
Clinuvel Pharmaceuticals Limited CUVL
$5.15
0.08
1.58%
October 29, 2026 3:50:09 PM
EST
Volume: 8,160
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Commentary & Analysis
Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Up 5.24%
As of Friday, October 16, Clinuvel Pharmaceuticals Limited’s CUVL share price has surged by 5.24%, which has investors questioning if this is right time to sell.Michael Rose
Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Down 7.36%
As of Thursday, October 15, Clinuvel Pharmaceuticals Limited’s CUVL share price has dipped by 7.36%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Down 5.14%
As of Monday, October 05, Clinuvel Pharmaceuticals Limited’s CUVL share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Clinuvel Pharmaceuticals Limited’s (CUVL) Stock Is Down 5.64%
As of Monday, October 05, Clinuvel Pharmaceuticals Limited’s CUVL share price has dipped by 5.64%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $255.4 | $232.8 | 30% |
|
| Shares Out (Mil) | 35.2 | 53.4 | 40% |
|
| Institutional Ownership | 69.9% | 92.9% | 43% |
|
| Float (Mil) | 42.1 | 41.2 | 43% |
|
| Beta | 0.57 | 0.96 | 32% |
|
| Avg Daily Volume (000s) | 6 | 490 | 15% |
|
| Price Change (52-week) |
(29.8%) | 48.2% | 30% |
|
| Growth | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 12.4% | 12.8% | 66% |
|
| Net Income (5yr) | 4.9% | (10.1%) | 47% |
|
| EPS (5yr) | 4.9% | 15.8% | 39 |
|
| Dividends (5yr) | 13.1% | 0.0% | 53% |
|
| Cash Flow (5yr) | (19.2%) | (15.7%) | 35% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65 | $37 | 22% |
|
| Net Income (TTM) (Mil) | $24 | ($44) | 50% |
|
| EPS (TTM) | $0.469 | ($1.600) | 53% |
|
| Operating Cash Flow (TTM) (Mil) | $26 | ($33) | 43% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $147 | $174 | 24% |
|
| Valuation | CUVL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.36 | 2.22 | 38% |
|
| P/E | 11.0 | 20.8 | 22% |
|
| Dividend Yield | 0.7% | 0.0% | 64% |
|
| PEG (5yr hist) | 2.2 | 1.1 | 71% |
|
| Ratios | CUVL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 83.2% | 66.9% | 90% |
|
| Net Margin | 36.1% | (75.3%) | 93% |
|
| ROA | 12.3% | (47.3%) | 90% |
|
| ROE | 13.5% | (53.3%) | 67% |
|
| Liabilities to Assets | 7.5% | 29.4% | 4% |
|
| F-Score | 4 | 2 | 34% |
|
Clinuvel Pharmaceuticals Limited did not pass any screens on 10/28/2026.
